Table 2.
Weekly percentage reduction in pain score
| Week | Peripheral neuropathic pain | Postherpetic neuralgia | ||
|---|---|---|---|---|
| Pregabalin (%) | Gabapentin 2400 mg (%) | Pregabalin (%) | Gabapentin 2400 mg (%) | |
| 1 | 13.7 | 17.2 | 14.7 | 17.3 |
| 2 | 23.2 | 24.2 | 23.3 | 24.9 |
| 3 | 29.9 | 27.5 | 29.5 | 29.2 |
| 4 | 39.1 | 29.9 | 40.3 | 31.2 |
| 5 | 44.4 | 31.5 | 46.6 | 32.7 |
| 6 | 44.2 | 32.7 | 43.9 | 33.7 |
| 7 | 45.0 | 33.6 | 43.9 | 34.5 |
| 8 | 46.3 | 34.2 | 45.1 | 35.0 |
| 9 | 49.8 | 34.6 | 49.1 | 35.4 |
| 10 | 51.1 | 34.9 | 50.6 | 35.7 |
| 11 | 53.3 | 35.2 | 57.5 | 35.9 |
| 12 | 54.1 | 35.3 | 58.2 | 36.0 |
The weekly percentage reductions in pain score are shown for each week of the model for both medications and populations. These percentages contribute to the transition probabilities within the Markov model